Conatus Endures Another NASH Setback With Failure To Hit Fibrosis Endpoint
Executive Summary
The pan-caspase inhibitor emricasan, partnered with Novartis, misses fibrosis-reduction endpoint in Phase IIb study, following the failure last December of a trial in portal hypertension.
You may also be interested in...
Conatus Accepts Defeat For Emricasan In NASH
After multiple Phase IIb trial failures, Conatus says it will fulfill contractual obligations and consider strategic alternatives. Partner Novartis was already focused on other candidates and partnerships in NASH.
Novartis’s NASH Chief: Our Strategy Is Combos With Tropifexor As ‘Backbone’
Novartis's broad but early-stage NASH pipeline will use FXR agonist tropifexor as its keystone for developing combination therapies with outside partners.
Intercept Retakes The Lead In NASH
A week after Gilead missed its primary endpoint in the first Phase III NASH trial, Intercept shows a statistically significant fibrosis benefit in Phase III with OCA. It plans to file for approval later this year.